|
| Status |
Public on Oct 15, 2014 |
| Title |
Primary_Tumor-CT_222_PEC |
| Sample type |
RNA |
| |
|
| Source name |
Tissue samples taken from colorectal cancer patients
|
| Organism |
Homo sapiens |
| Characteristics |
tissue: Primary Tumor
patient number: 209
Sex: Male
age: 52
who performance status: 1
tumor location: Left colon
differentiation: Moderate
pn: pN0
pt: pT3
folfiri status: NR
|
| Treatment protocol |
Samples were collected before chemotherapy
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Rneasy kit (Qiagen) for total RNA was performed according to the manufacturer's instructions.
|
| Label |
biotin
|
| Label protocol |
Biotinylated cRNA were prepared according to the Affymetrix IVT protocol from 3µg total RNA (3'IVT ExpressTechnical Manual).
|
| |
|
| Hybridization protocol |
Following fragmentation, 15 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Human Genome U133B Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450 with HWS kit.
|
| Scan protocol |
GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.
|
| Data processing |
Signal intensity for each transcript and detection call (present, absent, or marginal) were determined using MAS 5.0 Software (Affymetrix). Interarray normalization was performed using a set of internal standard genes (normalization set ϩ internal controls) leading to the determination of a scaling factor.
|
| |
|
| Submission date |
Oct 14, 2014 |
| Last update date |
Oct 15, 2014 |
| Contact name |
Pierre Martineau |
| E-mail(s) |
pierre.martineau@inserm.fr
|
| Phone |
+33 4 67 61 37 43
|
| Organization name |
Inserm
|
| Department |
IRCM
|
| Street address |
208 Rue des Apothicaires
|
| City |
Montpellier Cedex 5 |
| ZIP/Postal code |
34298 |
| Country |
France |
| |
|
| Platform ID |
GPL97 |
| Series (2) |
| GSE62321 |
Specific extracellular matrix remodeling signature of colon hepatic metastases [HG-U133B] |
| GSE62322 |
Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan |
|
